Omalizumab, an innovative treatment, could revolutionize the management of multiple food allergies. In particular, a study examines its ability to increase the threshold of tolerance to food allergens, paving the way for safer and more effective therapeutic options.
Food allergies represent a major public health concern, affecting millions of people around the world. Faced with this reality, oral immunotherapy for peanut allergies is the only approved option to date, leaving an unmet need for the treatment of other food allergies. In this context, omalizumab, an antibody monoclonalmonoclonal anti-IgEIgE, emerges as a beacon of hope, offering a new perspective for the management of individuals with multiple food allergies. The results of a very promising clinical trial were recently published in the NEJM.
Omalizumab, a real novelty
This innovative study explored the effectiveness and safety of omalizumab in people with allergies to several foods, including peanut. By recruiting subjects aged 1 to 55 and administering them either omalizumab or a placebo, the researchers aimed to increase the threshold of tolerance to allergensallergens specific. The results were remarkable, revealing that participants treated with omalizumab tolerated allergen doses significantly better compared to the group placeboplacebowith notable improvements in tolerance to peanut, milk, cashew nutscashew nuts and eggs.
This study marks a potential turning point in the treatment of food allergies, suggesting that omalizumab could offer a safe and effective alternative to increase the quality of life of allergy sufferers. However, despite these promising advances, further research is still needed to confirm these results and integrate omalizumab into therapeutic strategies against multiple food allergies.
